Coherus BioSciences (NASDAQ:CHRS) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a $12.00 price target on the biotechnology company’s stock. Separately, Truist Financial cut their price target on shares of Coherus BioSciences from $8.00 to $7.00 […]

Related Keywords

United States ,Coherus Biosciences ,Barclays Plc ,Vanguard Group Inc ,Coherus Biosciences Company Profile ,Rafferty Asset Management ,Coherus Biosciences Inc ,Brandywine Global Investment Management ,Cm Management ,Nasdaq ,Free Report ,Truist Financial ,Moderate Buy ,Get Free Report ,Asset Management ,Global Investment Management ,Coherus Biosciences Daily ,